Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -1.52
- Piotroski Score 3.00
- Grade Buy
- Symbol (XERS)
- Company Xeris Biopharma Holdings, Inc.
- Price $2.91
- Changes Percentage (4.3%)
- Change $0.12
- Day Low $2.75
- Day High $2.92
- Year High $3.26
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/08/2024
- Fiscal Year End N/A
- Average Stock Price Target $4.75
- High Stock Price Target $6.50
- Low Stock Price Target $3.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.47
- Trailing P/E Ratio -4.96
- Forward P/E Ratio -4.96
- P/E Growth -4.96
- Net Income $-62,255,000
Income Statement
Quarterly
Annual
Latest News of XERS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Joel Embiid, Sixers Focused On Big Picture In 2024-25 NBA Season
The Philadelphia 76ers, led by Joel Embiid, have excelled in the regular season but faced playoff challenges. Prioritizing Embiid's health, they've added depth with Andre Drummond and Paul George to a...
By Forbes | 17 hours ago -
Mayor Hopes Sixers' New Arena Could Help Philadelphia Land A WNBA Team
Philadelphia Mayor Cherelle Parker announced a new arena deal with the Philadelphia 76ers to secure the team in the city. The deal could also attract a WNBA team. The Sixers are interested in hosting ...
By Forbes | 5 days ago -
4 Ways Gen Xers Can Save for Retirement While Caring for Parents and Kids
Gen Xers are facing financial strain as part of the "Sandwich Generation" caring for kids and aging parents. Tips include earning passive income, involving family in caregiving, automating retirement ...
By Yahoo! Finance | 1 week ago